Octapharma presents research on congenital & acquired bleeding disorders at ASH Meeting

December 03, 2020

PARAMUS, N.J. (December 3, 2020) - Octapharma USA will present multiple clinical research posters focused on the efficacy and safety of fibryga®, Fibrinogen (Human) Lyophilized Powder for Reconstitution, for Intravenous Use in the treatment of congenital and acquired bleeding disorders during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, a virtual medical congress to be held December 5 - 8.

The research focused on fibryga® addresses the therapy's safety and efficacy to treat congenital fibrinogen (Factor 1) deficiency, a rare, inherited blood disorder where the blood does not clot normally, during on-demand bleeding episodes and surgical prophylaxis in adults and pediatrics. Additionally, Octapharma will present fibryga® research evaluating the product's hemostatic efficacy in acquired fibrinogen deficiency, a condition affecting non-surgical and surgical bleeding patients, including cardiac surgery, post-partum hemorrhage and trauma patients.

"Octapharma is determined to advance clinical research and treatment options for people with life-threatening bleeding disorders, including Factor 1 deficiency and other rare conditions," said Octapharma USA President Flemming Nielsen. "The National Hemophilia Foundation recently updated its treatment guidelines for Factor 1 deficiency to include fibryga® so the ASH research we will be presenting continues to add important clinical treatment data for this therapy. We look forward to sharing the latest research developments with the medical community."

The fibryga® focused research includes: Octapharma will also present research focused on Octaplas™, Pooled Plasma (Human), Solvent/Detergent (S/D) Treated Solution for Intravenous Infusion, entitled, "Retrospective Analysis of the Efficacy of Solvent/Detergent Treated Pooled Plasma As Compared to Fresh Frozen Plasma in Thrombotic Thrombocytopenic Purpura (TTP): A Single Center Experience." The study confirmed previously reported efficacy of Octaplas™ for treating suspected/confirmed TTP. There were no significant differences in thromboembolic or bleeding events between patients who received FFP as compared to Octaplas™. Presenter: Catherine Klapheke, University of Rochester Medical Center, Rochester, N.Y.

Finally, ASH attendees will have the opportunity to review research focused on another product, octaplex® Human Prothrombin Complex, freeze dried powder and solvent for solution for injection, which is not licensed in the U.S. The posters are:
-end-
About fibryga®

Fibryga®, Fibrinogen (Human) Lyophilized Powder for Reconstitution, for Intravenous Use, is a human fibrinogen concentrate indicated for the treatment of acute bleeding episodes in adults and adolescents with congenital fibrinogen deficiency, including afibrinogenemia and hypofibrinogenemia. Fibryga® is not indicated for dysfibrinogenemia. Fibryga® is stored as a lyophilized powder at room temperature or refrigerated temperature [+2°C to + 25°C (36°F to 77°F)] for up to 30 months from the date of manufacture. The product can be reconstituted with sterile water within approximately 5 to 10 minutes with the provided Octajet transfer device and particle filter (17-micron).

CONTRAINDICATIONS

Fibryga® is contraindicated in individuals who have manifested severe immediate hypersensitivity reactions, including anaphylaxis, to fibryga® or its components.

WARNINGS AND PRECAUTIONSThe fibryga® manufacturing process includes a solvent/detergent (S/D) step for virus inactivation, and a nanofiltration step (Planova 20N nanofilter or Pegasus SV4 nanofilter) for virus removal. For complete prescribing information, please visit fibrygausa.com.

About Octaplas™

Octaplas™ is a solvent/detergent (S/D) treated, pooled human plasma indicated for replacement of multiple coagulation factors in patients with acquired deficiencies due to liver disease or who are undergoing cardiac surgery or liver transplantation; and plasma exchange in patients with thrombotic thrombocytopenic purpura (TTP).

WARNINGS AND PRECAUTIONS

Transfusion reactions can occur with ABO blood group mismatches; high infusion rates can induce hypervolemia with consequent pulmonary edema or heart failure; excessive bleeding due to hyperfibrinolysis can occur due to low levels of alpha 2-antiplasmin; thrombosis can occur due to low levels of Protein S; citrate toxicity can occur with volumes exceeding one milliliter of Octaplas™ per kg per minute; Octaplas™ is made from human blood and may carry the risk of transmitting infectious agents, e.g., viruses and theoretically, the variant Creutzfeldt-Jakob disease and Creutzfeldt-Jakob disease agent.

For complete prescribing information, please visit octaplasus.com.

About the Octapharma Group

Headquartered in Lachen, Switzerland, Octapharma is one of the largest human protein products manufacturers in the world and has been committed to patient care and medical innovation since 1983. Its core business is the development and production of human proteins from human plasma and human cell lines. Octapharma employs more than 10,000 people worldwide to support the treatment of patients in over 115 countries with products across the following therapeutic areas: Hematology (coagulation disorders), Immunotherapy (immune disorders) and Critical Care. The company's American subsidiary, Octapharma USA, is located in Paramus, N.J. Octapharma operates three state-of-the-art production sites licensed by the U.S. Food and Drug Administration (FDA), providing a high level of production flexibility. For more information, please visit http://www.octapharmausa.com.

MEDIA CONTACT:

Anita Callari
Yankee Public Relations
anita@yankeepr.com
908-425-4878

Yankee Public Relations

Related Trauma Patients Articles from Brightsurf:

UAlberta researchers find way to speed up nerve regrowth for trauma patients
A University of Alberta researcher has found a treatment that increases the speed of nerve regeneration by three to five times, leading to much better outcomes for trauma surgery patients.

Whole body scans for trauma patients saves time spent in emergency departments
A new study by a University of South Australia medical imaging student may have found the solution to easing hospital ramping and crowded emergency departments.

Certain scores may predict which trauma patients face high risk of multiple infections
A team at Massachusetts General Hospital has found that certain scores already used to assess the severity of a trauma patient's condition can provide clues to their risk for multiple infections.

Giving trauma patients blood pressure stabilizing hormone cuts transfusions by half
Giving trauma patients with severe blood loss the hormone arginine vasopressin (AVP) cut the volume of blood products required to stabilize them by half, according to results of a new, first-of-its-kind clinical trial from Penn Medicine.

Initial clinical experience of zero TE skull MRI in patients with head trauma
Zero TE (ZTE) skull magnetic resonance imaging (MRI) can be a possible option for clinical use in patients with skull lesions and may be helpful in managing radiosensitive trauma patients, according to a study to be presented at the ARRS 2019 Annual Meeting, set for May 5-10 in Honolulu, Hawaii.

Childhood trauma has lasting effect on brain connectivity in patients with depression
A study lead by Penn Medicine researchers found that childhood trauma is linked to abnormal connectivity in the brain in adults with major depressive disorder (MDD).

Jury still out on what confers survival advantage in female trauma patients
Female hormones, particularly estrogen, do not seem to explain why women tend to have higher survival rates than men following severe trauma, an 11-year study using data from 815,843 Swedish patients suggests.

Artificial intelligence can identify trauma patients who misuse alcohol
A first-of-its kind study has demonstrated that an artificial intelligence technique can be used to identify trauma patients who misuse alcohol.

Gunshot victims require much more blood and are more likely to die than other trauma patients
In a new analysis of data submitted to Maryland's state trauma registry from 2005 to 2017, Johns Hopkins Medicine researchers found that gunshot victims are approximately five times more likely to require blood transfusions, they require 10 times more blood units and are 14 times more likely to die than people seriously injured by motor vehicles, non-gun assaults, falls or stabs.

Blood type O patients may have higher risk of death from severe trauma
Blood type O is associated with high death rates in severe trauma patients, according to a study published in the open-access journal Critical Care that involved 901 Japanese emergency care patients.

Read More: Trauma Patients News and Trauma Patients Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.